DiaSorin (OTCMKTS:DSRLF) Shares Gap Up – Time to Buy?

DiaSorin S.p.A. (OTCMKTS:DSRLF)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $67.00, but opened at $80.35. DiaSorin shares last traded at $80.35, with a volume of 100 shares changing hands.

Analyst Upgrades and Downgrades

DSRLF has been the topic of several research reports. Zacks Research raised DiaSorin to a “hold” rating in a research report on Tuesday, May 12th. UBS Group downgraded DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of DiaSorin in a research note on Tuesday, February 10th. Two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold”.

DiaSorin Stock Performance

The firm has a 50 day moving average price of $69.18 and a two-hundred day moving average price of $74.57.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.